{
    "nct_id": "NCT05259839",
    "official_title": "A Dose Escalation and Expansion Study of Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Patients With Newly Diagnosed or Relapsed/Refractory Multiple Myeloma",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance of <= 2.\n* Must have confirmed diagnosis of Relapsed/Refractory (R/R) Multiple Myeloma (MM) with documented evidence of progression during or after the participant's last treatment regimen based on the investigator's determination of the International Myeloma Working Group (IMWG) criteria.\n* Must have measurable disease as determined by central lab as outlined in the protocol.\n* Must be naïve to treatment with Etentamig.\n* Must have never received BCMA-targeted therapy. Participants who have received targeted therapy against non-BCMA targets will not be excluded.\n* Arms A, B and C: Participant has received at least 3 prior lines of MM treatment.\n* Arm E: Participant has received 1-3 prior lines of MM treatment.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Received a peripheral autologous stem cell transplant (SCT) within 12 weeks, or an allogeneic SCT within 1 year of the first dose of study treatment.\n* Unresolved adverse event (AE)s >= Grade 2 (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE] version 5.0) from prior anticancer therapy.\n* Has any of the following conditions:\n\n  * Nonsecretory Multiple Myeloma (MM).\n  * Active Plasma cell leukemia i.e., either 20% of peripheral white blood cells or > 2.0 × 10^9L circulating plasma cells by standard differential.\n  * Waldenstrom's macroglobulinemia.\n  * Light chain amyloidosis.\n  * Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin changes (POEMS) syndrome.\n  * Major surgery within 4 weeks prior to first dose or planned study participation.\n  * Acute infections within 14 days prior to first dose of study requiring therapy (antibiotic, antifungal or antiviral).\n  * Uncontrolled diabetes or hypertension within 14 days prior to first dose.\n  * Peripheral neuropathy >= Grade 3 or >= Grade 2 with pain within 2 weeks prior to first dose.",
    "miscellaneous_criteria": ""
}